Multidrug-Resistant Bacteria in Hematology Patients: Emerging Threats

References

• Boucher HW, Talbot GH, Bradley JS et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin. Infect. Dis. 48 (1 ), 1 – 12 (2009).
   PubMed Web of Science ®Google Scholar
• Rice LB. Progress and challenges in implementing the research on ESKAPE pathogens. Infect. Control Hosp. Epidemiol. 31 (Suppl. 1 ), S7 – S10 (2010).
   PubMed Web of Science ®Google Scholar
• ECDC. European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2014. Annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). Stockholm: ECDC (2015). http://ecdc.europa.eu
   Google Scholar
• Weiner LM, Fridkin SK, Aponte-Torres Z et al. Vital signs: preventing antibiotic-resistant infections in hospitals – United States, 2014. MMWR Morb. Mortal. Wkly Rep. 65 (9 ), 235 – 241 (2016).
   PubMed Web of Science ®Google Scholar
• Penack O, Becker C, Buchheidt D et al. Management of sepsis in neutropenic patients: 2014 updated guidelines from the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO). Ann. Hematol. 93 (7 ), 1083 – 1095 (2014).
   PubMed Web of Science ®Google Scholar
• Jeddi R, Achour M, Amor RB et al. Factors associated with severe sepsis: prospective study of 94 neutropenic febrile episodes. Hematology 15 (1 ), 28 – 32 (2010).
   PubMed Web of Science ®Google Scholar
• Kang CI, Song JH, Chung DR et al. Risk factors and pathogenic significance of severe sepsis and septic shock in 2286 patients with gram-negative bacteremia. J. Infect. 62 (1 ), 26 – 33 (2011).
   PubMed Web of Science ®Google Scholar
• Viscoli C, Varnier O, Machetti M. Infections in patients with febrile neutropenia: epidemiology, microbiology, and risk stratification. Clin. Infect. Dis. 40 (Suppl. 4 ), S240 – S245 (2005).
   PubMed Web of Science ®Google Scholar
• Klastersky J, Ameye L, Maertens J et al. Bacteraemia in febrile neutropenic cancer patients. Int. J. Antimicrob. Agents 30 (Suppl. 1 ), S51 – S59 (2007).
   PubMed Web of Science ®Google Scholar
• Mikulska M, Viscoli C, Orasch C et al. Aetiology and resistance in bacteraemias among adult and paediatric haematology and cancer patients. J. Infect. 68 (4 ), 321 – 331 (2014).
   PubMed Web of Science ®Google Scholar
• Gudiol C, Tubau F, Calatayud L et al. Bacteraemia due to multidrug-resistant Gram-negative bacilli in cancer patients: risk factors, antibiotic therapy and outcomes. J. Antimicrob. Chemother. 66 (3 ), 657 – 663 (2011).
   PubMed Web of Science ®Google Scholar
• Tumbarello M, Spanu T, Caira M et al. Factors associated with mortality in bacteremic patients with hematologic malignancies. Diagn. Microbiol. Infect. Dis. 64 (3 ), 320 – 326 (2009).
   PubMed Web of Science ®Google Scholar
• Castagnola E, Mikulska M, Viscoli C. Prophylaxis and empirical therapy of infection in cancer patients. In : Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases, (8th Edition). Bennett JE, Dolin R, Blaser MJ( Eds ) . Elsevier Saunders, Philadelphia, PA, USA, 3395 – 3413 (2015).
   Google Scholar
• Klastersky J. Science and pragmatism in the treatment and prevention of neutropenic infection. J. Antimicrob. Chemother. 41 (Suppl. D ), 13 – 24 (1998).
   PubMed Web of Science ®Google Scholar
• Gudiol C, Bodro M, Simonetti A et al. Changing aetiology, clinical features, antimicrobial resistance, and outcomes of bloodstream infection in neutropenic cancer patients. Clin. Microbiol. Infect. 19 (5 ), 474 – 479 (2013).
   PubMed Web of Science ®Google Scholar
• Mikulska M, Del Bono V, Raiola AM et al. Blood stream infections in allogeneic hematopoietic stem cell transplant recipients: reemergence of gram-negative rods and increasing antibiotic resistance. Biol. Blood Marrow Transplant. 15 (1 ), 47 – 53 (2009).
   PubMed Web of Science ®Google Scholar
• Chong Y, Yakushiji H, Ito Y, Kamimura T. Cefepime-resistant gram-negative bacteremia in febrile neutropenic patients with hematological malignancies. Int. J. Infect. Dis. 14 (Suppl. 3 ), e171 – e175 (2010).
   PubMedGoogle Scholar
• Jacobson K, Rolston K, Elting L, LeBlanc B, Whimbey E, Ho DH. Susceptibility surveillance among gram-negative bacilli at a cancer center. Chemotherapy 45 (5 ), 325 – 334 (1999).
   PubMed Web of Science ®Google Scholar
• Oliveira AL, de Souza M, Carvalho-Dias VM et al. Epidemiology of bacteremia and factors associated with multi-drug-resistant gram-negative bacteremia in hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 39 (12 ), 775 – 781 (2007).
   PubMed Web of Science ®Google Scholar
• Lang A, De Fina G, Meyer R et al. Comparison of antimicrobial use and resistance of bacterial isolates in a haematology ward and an intensive care unit. Eur. J. Clin. Microbiol. Infect. Dis. 20 (9 ), 657 – 660 (2001).
   PubMed Web of Science ®Google Scholar
• Trecarichi EM, Tumbarello M, Caira M et al. Multidrug resistant Pseudomonas aeruginosa bloodstream infection in adult patients with hematological malignancies. Haematologica 96 (1 ), e1 – e3 (2011).
   PubMed Web of Science ®Google Scholar
• Sood P, Seth T, Kapil A et al. Emergence of multidrug resistant Acinetobacter blood stream infections in febrile neutropenia patients with haematological cancers and bone marrow failure syndromes. J. Indian Med. Assoc. 110 (7 ), 439 – 444 (2012).
   PubMedGoogle Scholar
• Moghnieh R, Estaitieh N, Mugharbil A et al. Third generation cephalosporin resistant Enterobacteriaceae and multidrug resistant gram-negative bacteria causing bacteremia in febrile neutropenia adult cancer patients in Lebanon, broad spectrum antibiotics use as a major risk factor, and correlation with poor prognosis. Front. Cell Infect. Microbiol. 5, 11 (2015).
   PubMed Web of Science ®Google Scholar
• Trecarichi EM, Pagano L, Candoni A et al. Current epidemiology and antimicrobial resistance data for bacterial bloodstream infections in patients with hematologic malignancies: an Italian multicentre prospective survey. Clin. Microbiol. Infect. 21 (4 ), 337 – 343 (2015).
   PubMed Web of Science ®Google Scholar
• Canton R, Akova M, Carmeli Y et al. Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe. Clin. Microbiol. Infect. 18 (5 ), 413 – 431 (2012).
   PubMed Web of Science ®Google Scholar
• Chen CY, Tsay W, Tang JL et al. Epidemiology of bloodstream infections in patients with haematological malignancies with and without neutropenia. Epidemiol. Infect. 138 (7 ), 1044 – 1051 (2010).
   PubMed Web of Science ®Google Scholar
• Van der Bij AK, Van der Zwan D, Peirano G et al. Metallo-beta-lactamase-producing Pseudomonas aeruginosa in The Netherlands: the nationwide emergence of a single sequence type. Clin. Microbiol. Infect. 18 (9 ), e369 – e372 (2012).
   PubMed Web of Science ®Google Scholar
• Schwaber MJ, Lev B, Israeli A et al. Containment of a country-wide outbreak of carbapenem-resistant Klebsiella pneumoniae in Israeli hospitals via a nationally implemented intervention. Clin. Infect. Dis. 52 (7 ), 848 – 855 (2011).
   PubMed Web of Science ®Google Scholar
• Fournier S, Monteil C, Lepainteur M et al. Long-term control of carbapenemase-producing Enterobacteriaceae at the scale of a large French multihospital institution: a nine-year experience, France, 2004 to 2012. Euro. Surveill. 19 (19 ), pii: 20802 (2014).
   Google Scholar
• Giannella M, Trecarichi EM, De Rosa FG et al. Risk factors for carbapenem-resistant Klebsiella pneumoniae bloodstream infection among rectal carriers: a prospective observational multicentre study. Clin. Microbiol. Infect. 20 (12 ), 1357 – 1362 (2014).
   PubMed Web of Science ®Google Scholar
• Livermore DM. Fourteen years in resistance. Int. J. Antimicrob. Agents 39 (4 ), 283 – 294 (2012).
   PubMed Web of Science ®Google Scholar
• Sutter DE, Milburn E, Chukwuma U, Dzialowy N, Maranich AM, Hospenthal DR. Changing susceptibility of Staphylococcus aureus in a US pediatric population. Pediatrics pii: peds.2015-3099 (2016 ) ( Epub ahead of print).
   PubMedGoogle Scholar
• Kamboj M, Chung D, Seo SK et al. The changing epidemiology of vancomycin-resistant Enterococcus (VRE) bacteremia in allogeneic hematopoietic stem cell transplant (HSCT) recipients. Biol. Blood Marrow Transplant. 16 (11 ), 1576 – 1581 (2010).
   PubMed Web of Science ®Google Scholar
• Barber KE, King ST, Stover KR, Pogue JM. Therapeutic options for vancomycin-resistant enterococcal bacteremia. Expert Rev. Anti. Infect. Ther. 13 (3 ), 363 – 377 (2015).
   PubMed Web of Science ®Google Scholar
• Tumbarello M, Sali M, Trecarichi EM et al. Bloodstream infections caused by extended-spectrum-beta-lactamase- producing Escherichia coli: risk factors for inadequate initial antimicrobial therapy. Antimicrob. Agents Chemother. 52 (9 ), 3244 – 3252 (2008).
   PubMed Web of Science ®Google Scholar
• Kang CI, Chung DR, Ko KS, Peck KR, Song JH ; Korean Network for Study of Infectious Diseases. Risk factors for infection and treatment outcome of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae bacteremia in patients with hematologic malignancy. Ann. Hematol. 91 (1 ), 115 – 121 (2012).
   PubMed Web of Science ®Google Scholar
• Mikulska M, Del Bono V, Bruzzi P et al. Mortality after bloodstream infections in allogeneic haematopoietic stem cell transplant (HSCT) recipients. Infection 40 (3 ), 271 – 278 (2012).
   PubMed Web of Science ®Google Scholar
• Girmenia C, Rossolini GM, Piciocchi A et al. Infections by carbapenem-resistant Klebsiella pneumoniae in SCT recipients: a nationwide retrospective survey from Italy. Bone Marrow Transplant. 50 (2 ), 282 – 288 (2015).
   PubMed Web of Science ®Google Scholar
• Gyssens IC, Kern WV, Livermore DM ; ECIL-4, a joint venture of EBMT, EORTC, ICHS and ESGICH of ESCMID. The role of antibiotic stewardship in limiting antibacterial resistance among hematology patients. Haematologica 98 (12 ), 1821 – 1825 (2013).
   PubMed Web of Science ®Google Scholar
• Kjellander C, Bjorkholm M, Cherif H, Kalin M, Giske CG. Hematological: Low all-cause mortality and low occurrence of antimicrobial resistance in hematological patients with bacteremia receiving no antibacterial prophylaxis: a single-center study. Eur. J. Haematol. 88 (5 ), 422 – 430 (2012).
   PubMed Web of Science ®Google Scholar
• Kim SH, Kwon JC, Choi SM et al. Escherichia coli and Klebsiella pneumoniae bacteremia in patients with neutropenic fever: factors associated with extended-spectrum beta-lactamase production and its impact on outcome. Ann. Hematol. 92 (4 ), 533 – 541 (2013).
   PubMed Web of Science ®Google Scholar
• Trecarichi EM, Tumbarello M, Spanu T et al. Incidence and clinical impact of extended-spectrum-beta-lactamase (ESBL) production and fluoroquinolone resistance in bloodstream infections caused by Escherichia coli in patients with hematological malignancies. J. Infect. 58 (4 ), 299 – 307 (2009).
   PubMed Web of Science ®Google Scholar
• Kim SB, Min YH, Cheong JW et al. Incidence and risk factors for carbapenem- and multidrug-resistant Acinetobacter baumannii bacteremia in hematopoietic stem cell transplantation recipients. Scand. J. Infect. Dis. 46 (2 ), 81 – 88 (2014).
   PubMed Web of Science ®Google Scholar
• Averbuch D, Orasch C, Cordonnier C et al. European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia. Haematologica 98 (12 ), 1826 – 1835 (2013).
   PubMed Web of Science ®Google Scholar
• Mermel LA, Allon M, Bouza E et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin. Infect. Dis. 49 (1 ), 1 – 45 (2009).
   PubMed Web of Science ®Google Scholar
• Mollee P, Jones M, Stackelroth J et al. Catheter-associated bloodstream infection incidence and risk factors in adults with cancer: a prospective cohort study. J. Hosp. Infect. 78 (1 ), 26 – 30 (2011).
   PubMed Web of Science ®Google Scholar
• Chaberny IF, Ruseva E, Sohr D et al. Surveillance with successful reduction of central line-associated bloodstream infections among neutropenic patients with hematologic or oncologic malignancies. Ann. Hematol. 88 (9 ), 907 – 912 (2009).
   PubMed Web of Science ®Google Scholar
• Metzger KE, Rucker Y, Callaghan M et al. The burden of mucosal barrier injury laboratory-confirmed bloodstream infection among hematology, oncology, and stem cell transplant patients. Infect. Control Hosp. Epidemiol. 36 (2 ), 119 – 124 (2015).
   PubMed Web of Science ®Google Scholar
• CDC. Device associated module BSI. Bloodstream infection event (central line-associated bloodstream infection and non-central line-associated bloodstream infection). www.cdc.gov/nhsn/PDFs/pscManual/4PSC_CLABScurrent.pdf
   Google Scholar
• Bucaneve G, Micozzi A, Menichetti F et al. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N. Engl. J. Med. 353 (10 ), 977 – 987 (2005).
   PubMed Web of Science ®Google Scholar
• Gafter-Gvili A, Fraser A, Paul M, Leibovici L. Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann. Intern. Med. 142 (12 Pt 1 ), 979 – 995 (2005).
   PubMed Web of Science ®Google Scholar
• Leibovici L, Paul M, Cullen M et al. Antibiotic prophylaxis in neutropenic patients: new evidence, practical decisions. Cancer 107 (8 ), 1743 – 1751 (2006).
   PubMed Web of Science ®Google Scholar
• McDonald LC, Killgore GE, Thompson A et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N. Engl. J. Med. 353 (23 ), 2433 – 2441 (2005).
   PubMed Web of Science ®Google Scholar
• Slavin MA, Lingaratnam S, Mileshkin L et al. Use of antibacterial prophylaxis for patients with neutropenia. Australian Consensus Guidelines 2011 Steering Committee. Intern. Med. J. 41 (1b ), 102 – 109 (2011).
   PubMed Web of Science ®Google Scholar
• Orasch C, Averbuch D, Mikulska M et al. Discontinuation of empirical antibiotic therapy in neutropenic leukaemia patients with fever of unknown origin is ethical. Clin. Microbiol. Infect. 21 (3 ), e25 – e27 (2015).
   PubMed Web of Science ®Google Scholar
• Paul M, Carmeli Y, Durante-Mangoni E et al. Combination therapy for carbapenem-resistant gram-negative bacteria. J. Antimicrob. Chemother. 69 (9 ), 2305 – 2309 (2014).
   PubMed Web of Science ®Google Scholar
• Tumbarello M, Viale P, Viscoli C et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin. Infect. Dis. 55 (7 ), 943 – 950 (2012).
   PubMed Web of Science ®Google Scholar
• Kim YJ, Jun YH, Kim YR et al. Risk factors for mortality in patients with Pseudomonas aeruginosa bacteremia; retrospective study of impact of combination antimicrobial therapy. BMC Infect. Dis. 14, 161 (2014).
   PubMed Web of Science ®Google Scholar
• Tumbarello M, Trecarichi EM, De Rosa FG et al. Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study. J. Antimicrob. Chemother. 70 (7 ), 2133 – 2143 (2015).
   PubMed Web of Science ®Google Scholar
• Daikos GL, Tsaousi S, Tzouvelekis LS et al. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob. Agents Chemother. 58 (4 ), 2322 – 2328 (2014).
   PubMed Web of Science ®Google Scholar
• Hachem RY, Chemaly RF, Ahmar CA et al. Colistin is effective in treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa in cancer patients. Antimicrob. Agents Chemother. 51 (6 ), 1905 – 1911 (2007).
   PubMed Web of Science ®Google Scholar
• Poulikakos P, Tansarli GS, Falagas ME. Combination antibiotic treatment versus monotherapy for multidrug-resistant, extensively drug-resistant, and pandrug-resistant Acinetobacter infections: a systematic review. Eur. J. Clin. Microbiol. Infect. Dis. 33 (10 ), 1675 – 1685 (2014).
   PubMed Web of Science ®Google Scholar
• Nation RL, Li J, Cars O et al. Consistent global approach on reporting of colistin doses to promote safe and effective use. Clin. Infect. Dis. 58 (1 ), 139 – 141 (2014).
   PubMed Web of Science ®Google Scholar
• Garonzik SM, Li J, Thamlikitkul V et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob. Agents Chemother. 55 (7 ), 3284 – 3294 (2011).
   PubMed Web of Science ®Google Scholar
• Plachouras D, Karvanen M, Friberg LE et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob. Agents Chemother. 53 (8 ), 3430 – 3436 (2009).
   PubMed Web of Science ®Google Scholar
• Dalfino L, Puntillo F, Mosca A et al. High-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study. Clin. Infect. Dis. 54 (12 ), 1720 – 1726 (2012).
   PubMed Web of Science ®Google Scholar
• Trifi A, Abdellatif S, Daly F et al. Efficacy and toxicity of high-dose colistin in multidrug-resistant gram-negative bacilli infections: a comparative study of a matched series. Chemotherapy 61 (4 ), 190 – 196 (2016).
   PubMed Web of Science ®Google Scholar
• Averbuch D, Cordonnier C, Livermore DM et al. Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: guidelines of the 4th European Conference on Infections in Leukemia (ECIL-4, 2011). Haematologica 98 (12 ), 1836 – 1847 (2013).
   PubMed Web of Science ®Google Scholar
• Lee CS, Doi Y. Therapy of infections due to carbapenem-resistant gram-negative pathogens. Infect. Chemother. 46 (3 ), 149 – 164 (2014).
   PubMedGoogle Scholar
• Ammerlaan HS, Kluytmans JA, Wertheim HF, Nouwen JL, Bonten MJ. Eradication of methicillin-resistant Staphylococcus aureus carriage: a systematic review. Clin. Infect. Dis. 48 (7 ), 922 – 930 (2009).
   PubMed Web of Science ®Google Scholar
• Climo MW, Yokoe DS, Warren DK et al. Effect of daily chlorhexidine bathing on hospital-acquired infection. N. Engl. J. Med. 368 (6 ), 533 – 542 (2013).
   PubMed Web of Science ®Google Scholar
• Hayden MK, Lin MY, Lolans K et al. Prevention of colonization and infection by Klebsiella pneumoniae carbapenemase-producing Enterobacteriaceae in long-term acute-care hospitals. Clin. Infect. Dis. 60 (8 ), 1153 – 1161 (2015).
   PubMed Web of Science ®Google Scholar
• CDC. Facility guidance for control of carbapenem resistant Enterobacteriaceae (CRE) November 2015. www.cdc.gov/hai/pdfs/cre/CRE-guidance-508.pdf
   Google Scholar
• Mondy KE, Shannon W, Mundy LM. Evaluation of zinc bacitracin capsules versus placebo for enteric eradication of vancomycin-resistant Enterococcus faecium. Clin. Infect. Dis. 33 (4 ), 473 – 476 (2001).
   PubMed Web of Science ®Google Scholar
• Hachem R, Raad I. Failure of oral antimicrobial agents in eradicating gastrointestinal colonization with vancomycin-resistant enterococci. Infect. Control Hosp. Epidemiol. 23 (1 ), 43 – 44 (2002).
   PubMed Web of Science ®Google Scholar
• Rieg S, Kupper MF, de With K, Serr A, Bohnert JA, Kern WV. Intestinal decolonization of Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBL): a retrospective observational study in patients at risk for infection and a brief review of the literature. BMC Infect. Dis. 15, 475 (2015).
   PubMed Web of Science ®Google Scholar
• Zuckerman T, Benyamini N, Sprecher H et al. SCT in patients with carbapenem resistant Klebsiella pneumoniae: a single center experience with oral gentamicin for the eradication of carrier state. Bone Marrow Transplant. 46 (9 ), 1226 – 1230 (2011).
   PubMed Web of Science ®Google Scholar
• Saidel-Odes L, Polachek H, Peled N et al. A randomized, double-blind, placebo-controlled trial of selective digestive decontamination using oral gentamicin and oral polymyxin E for eradication of carbapenem-resistant Klebsiella pneumoniae carriage. Infect. Control Hosp. Epidemiol. 33 (1 ), 14 – 19 (2012).
   PubMed Web of Science ®Google Scholar
• Oren I, Sprecher H, Finkelstein R et al. Eradication of carbapenem-resistant Enterobacteriaceae gastrointestinal colonization with nonabsorbable oral antibiotic treatment: a prospective controlled trial. Am. J. Infect. Control. 41 (12 ), 1167 – 1172 (2013).
   PubMed Web of Science ®Google Scholar
• Lubbert C, Faucheux S, Becker-Rux D et al. Rapid emergence of secondary resistance to gentamicin and colistin following selective digestive decontamination in patients with KPC-2-producing Klebsiella pneumoniae: a single-centre experience. Int. J. Antimicrob. Agents 42 (6 ), 565 – 570 (2013).
   PubMed Web of Science ®Google Scholar
• Tascini C, Sbrana F, Flammini S et al. Oral gentamicin gut decontamination for prevention of KPC-producing Klebsiella pneumoniae infections: relevance of concomitant systemic antibiotic therapy. Antimicrob. Agents Chemother. 58 (4 ), 1972 – 1976 (2014).
   PubMed Web of Science ®Google Scholar
• Tosh PK, McDonald LC. Infection control in the multidrug-resistant era: tending the human microbiome. Clin. Infect. Dis. 54 (5 ), 707 – 713 (2012).
   PubMed Web of Science ®Google Scholar
• Bush K. A resurgence of beta-lactamase inhibitor combinations effective against multidrug-resistant Gram-negative pathogens. Int. J. Antimicrob. Agents 46 (5 ), 483 – 493 (2015).
   PubMed Web of Science ®Google Scholar
• Liscio JL, Mahoney MV, Hirsch EB. Ceftolozane/tazobactam and ceftazidime/avibactam: two novel beta-lactam/beta-lactamase inhibitor combination agents for the treatment of resistant Gram-negative bacterial infections. Int. J. Antimicrob. Agents 46 (3 ), 266 – 271 (2015).
   PubMed Web of Science ®Google Scholar
• Lapuebla A, Abdallah M, Olafisoye O et al. Activity of meropenem combined with RPX7009, a novel beta-lactamase inhibitor, against gram-negative clinical isolates in New York City. Antimicrob. Agents Chemother. 59 (8 ), 4856 – 4860 (2015).
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Cheung D, Adam H et al. Review of eravacycline, a novel fluorocycline antibacterial Agent. Drugs 76 (5 ), 567 – 588 (2016).
   PubMed Web of Science ®Google Scholar
• Holmes NE, Howden BP. What’s new in the treatment of serious MRSA infection? Curr. Opin Infect. Dis. 27 (6 ), 471 – 478 (2014).
   PubMed Web of Science ®Google Scholar
• Rodvold KA, McConeghy KW. Methicillin-resistant Staphylococcus aureus therapy: past, present, and future. Clin. Infect. Dis. 58 (Suppl. 1 ), S20 – S27 (2014).
   PubMed Web of Science ®Google Scholar
• Roberts KD, Sulaiman RM, Rybak MJ. Dalbavancin and oritavancin: an innovative approach to the treatment of gram-positive infections. Pharmacotherapy 35 (10 ), 935 – 948 (2015).
   PubMed Web of Science ®Google Scholar
• Klinker KP, Borgert SJ. Beyond vancomycin: the tail of the lipoglycopeptides. Clin. Ther. 37 (12 ), 2619 – 2636 (2015).
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Love R, Adam H et al. Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens. Drugs 75 (3 ), 253 – 270 (2015).
   PubMed Web of Science ®Google Scholar
• Roberts JA, Paul SK, Akova M et al. DALI: defining antibiotic levels in intensive care unit patients: are current beta-lactam antibiotic doses sufficient for critically ill patients? Clin. Infect. Dis. 58 (8 ), 1072 – 1083 (2014).
   PubMed Web of Science ®Google Scholar
• Rhodes NJ, MacVane SH, Kuti JL, Scheetz MH. Impact of loading doses on the time to adequate predicted beta-lactam concentrations in prolonged and continuous infusion dosing schemes. Clin. Infect. Dis. 59 (6 ), 905 – 907 (2014).
   PubMed Web of Science ®Google Scholar
• Falagas ME, Tansarli GS, Ikawa K, Vardakas KZ. Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin/tazobactam: a systematic review and meta-analysis. Clin. Infect. Dis. 56 (2 ), 272 – 282 (2013).
   PubMed Web of Science ®Google Scholar